Photo: People's Daily

Clinical trials of Remdesivir have been conducted in several hospitals in Wuhan, and the results will be published on April 27, said He Zhimin, the deputy director of the National Intellectual Property Administration (NIPA) at a press conference of the joint prevention and control mechanism of the China’s State Council on Tuesday.

The antiviral drug hasn’t been approved for listing in any country in the world. Gilead Sciences has applied for 8 patents on Remdesivir-related drugs in China, of which 3 have been authorized and 5 are under review, covering chemical compounds, preparations, production methods and uses.

"We are concerned about the effectiveness and safety of Remdesivir and looking forward to see more effective antiviral drug," He said.

At the press conference, officials also introduced measures to maintain market order and support work resumption.

(Compiled by Yang Fan)